Replimune Group, Inc. (REPL) Competitors & Peers
The 5 largest companies in the same industry as Replimune Group, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $547.09 | P/E 35.2RSI 58Cap 138.9 B |
| REGN | Partner | $904.35 | P/E 20.0RSI 63Cap 93.6 B |
| ARGX | Peer | $927.21 | P/E 32.1RSI 56Cap 58.3 B |
| RVMD | Peer | $192.28 | RSI 50Cap 40.9 B |
| CSLLY | Peer | $34.65 | P/E 18.2RSI 71Cap 66.6 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- TMOSupplier
Thermo Fisher supplies biological bioreactors, cell culture media, and lab single-use systems to Replimune's manufacturing facilities.
Model-inferred, unverified — treat as a lead, not evidence - BMYPartner
Collaborates on clinical combination trials pairing Replimune's RP1 with BMS's Opdivo (nivolumab).
Model-inferred, unverified — treat as a lead, not evidence - REGNPartner
Collaborates on clinical trials combining RP1 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab).
Model-inferred, unverified — treat as a lead, not evidence - AMGNCompetitor
Competes in oncolytic immunotherapy; Amgen manufactures Imlygic (talimogene laherparepvec).
Model-inferred, unverified — treat as a lead, not evidence